View Older Stories View More Recent Stories

May 15, 2026 09:00AM Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
May 14, 2026 05:24PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 13, 2026 05:48PM Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 13, 2026 04:01PM Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
May 13, 2026 08:00AM Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
May 13, 2026 06:30AM Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 11, 2026 05:46PM Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
May 8, 2026 06:52AM Artiva Biotherapeutics prices $300 million stock and warrant offering
May 8, 2026 06:52AM Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 6, 2026 07:00AM CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma
May 4, 2026 07:30AM Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
May 1, 2026 04:11PM Form SCHEDULE 13G Altimmune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 29, 2026 06:44PM Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 28, 2026 05:16PM Form SCHEDULE 13G Prelude Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 28, 2026 07:00AM Climb Bio raises $110 million in private placement
Apr 28, 2026 07:00AM Climb Bio, Inc. Announces $110.0 Million Private Placement
Apr 27, 2026 04:46PM Form SCHEDULE 13G JATT II Acquisition Corp Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 27, 2026 07:00AM Altimmune closes $225 million public offering for liver drug development
Apr 27, 2026 07:00AM Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Apr 23, 2026 06:56PM Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 21, 2026 07:06PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 20, 2026 06:31AM Prelude Therapeutics prices $90 million stock offering at $4.44 per share
Apr 20, 2026 06:30AM Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Apr 17, 2026 04:57PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 17, 2026 08:00AM Tyra Biosciences appoints Habib Dable to board of directors
Apr 17, 2026 08:00AM Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Apr 15, 2026 05:31PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 15, 2026 07:30AM Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia
Apr 14, 2026 02:08PM Galera and Obsidian merge in $350 million all-stock deal
Apr 14, 2026 02:08PM Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Apr 14, 2026 08:54AM Obsidian Therapeutics and Galera Therapeutics announce merger with $350M funding
Apr 14, 2026 08:54AM Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Apr 14, 2026 06:05AM Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC¹ Pipeline in Oncology
Apr 14, 2026 06:00AM Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
Apr 13, 2026 05:23PM Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 10, 2026 06:25PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 8, 2026 06:45PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 8, 2026 07:00AM Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
Apr 7, 2026 06:00PM Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 7, 2026 04:14PM Form SCHEDULE 13G OnKure Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 6, 2026 06:55PM Form SCHEDULE 13G Zai Lab Ltd Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 6, 2026 07:00AM Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointil
Apr 2, 2026 04:47PM Form SCHEDULE 13G Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 1, 2026 05:10PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 1, 2026 07:05AM Cyclerion and Korsana announce $380 million merger deal
Apr 1, 2026 07:05AM Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Mar 31, 2026 07:30AM CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma
Mar 30, 2026 08:38PM Form SCHEDULE 13G Xencor Inc Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 30, 2026 08:32PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 30, 2026 08:01AM Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
View More Recent Stories View Older Stories